India Insulin Delivery Devices Market By Product Type (Pens, Pumps, Pen Needles, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By End User (Hospitals & Clinics, Homecare, Others), By Region, Competition, Forecast and Opportunities, 2020-2030F

Market Overview

India Insulin Delivery Devices Market was valued at USD 1.06 Billion in 2024 and is expected to reach USD 1.68 Billion by 2030 with a CAGR of 7.90% during the forecast period. 

Insulin delivery devices constitute essential medical tools and systems designed to administer insulin, a hormone critical for regulating blood sugar levels in individuals with diabetes. These devices facilitate the controlled and precise administration of insulin to maintain blood sugar within target ranges. Among these devices are insulin pens, resembling pens in shape and size, which offer easy and accurate dose settings through pre-filled or replaceable insulin cartridges. Insulin pumps, small electronic devices, provide a continuous insulin supply via a catheter inserted under the skin, allowing for precise control with adjustable basal rates and bolus doses. Additionally, microneedle patches, utilizing tiny needles for painless insulin delivery through the skin, offer a less invasive alternative to injections.

The preference for insulin delivery devices such as pens and pumps over traditional syringes and vials is driven by factors like ease of use, convenience, and improved quality of life for patients. Continuous innovation in device technology, including smart pumps and connected devices, further boosts their adoption rates by enhancing diabetes management. Increasing awareness about diabetes, its complications, and the significance of proper management fuels the demand for insulin delivery devices. Healthcare providers and organizations play a vital role in this process through patient education programs, helping individuals gain a better understanding of diabetes management, including the utilization of insulin delivery devices.

Key Market Drivers

Technological Advancements

Technological advancements are a major driver of the India insulin delivery devices market because diabetes care is steadily shifting from basic injection support to connected, precision-led, and patient-friendly delivery systems that improve control in everyday life. In a country where official estimates place the number of people living with diabetes at 101 million, device innovation matters not only for convenience but also for long-term adherence, dose accuracy, and the reduction of avoidable complications.

Smart insulin pens are strengthening this transition by automatically recording the time, date, and amount of insulin delivered, while app connectivity allows dosing information to be viewed alongside glucose readings so that patients and doctors can make more informed treatment decisions. Advanced insulin pump systems are also reshaping care by combining insulin delivery with continuous sensing and automated correction features that reduce the burden of constant manual adjustment. For instance, Medtronic’s MiniMed 780G system in India automatically adjusts insulin delivery and corrects high glucose levels every five minutes, showing how device intelligence is making therapy more responsive and less dependent on repeated user intervention.

At the same time, improvements in user interface design, portability, and digital sharing are making these devices more practical for routine use across home care and remote consultations. As technology continues to make insulin delivery more precise, more comfortable, and easier to manage, it is creating a stronger value proposition for both patients and providers across India.

Shifting Patient Preference for Insulin Delivery Devices

Shifting patient preference is becoming a powerful driver of the India insulin delivery devices market because people increasingly want insulin administration to be discreet, simple, portable, and less disruptive to work, travel, and daily routines. This change is especially important in India, where the diabetes burden is extremely large and many patients need solutions that fit long treatment journeys without adding fear, complexity, or social discomfort. Insulin pens and pump-based systems are gaining attention because they support more convenient dosing, reduce the inconvenience associated with traditional vial-and-syringe methods, and align better with the expectations of patients who are becoming more familiar with digital health tools.

Connected features such as dose memory and app-linked data review also make these devices more attractive to younger and urban users who expect healthcare products to be intuitive and trackable. For instance, an audit conducted in a large Indian diabetes care setting found that 66.08 people out of every 100 insulin users relied on pen devices, while 31.76 used syringes, clearly indicating that patient choice moves toward delivery formats that offer greater ease and confidence.

Cost still remains a constraint for wider adoption, yet access-oriented public health efforts and affordable medicine channels are helping sustain diabetes treatment engagement at a broader level. As awareness grows and device design improves, patient preference is increasingly shifting from mere insulin availability to better delivery experience, which is supporting continued market expansion in India.

Increasing Healthcare Awareness

Increasing healthcare awareness is a key factor accelerating demand for insulin delivery devices in India because earlier diagnosis, stronger understanding of diabetes risks, and better treatment literacy are pushing more patients toward timely and structured disease management. Government-led screening, frontline health worker outreach, and continuous non-communicable disease education have expanded the conversation from simple blood sugar detection to sustained control, complication prevention, and adherence to prescribed therapy.

This matters greatly in India because official sources note that 101 million people are living with diabetes and 136 million with prediabetes, which means awareness is not only a preventive tool but also a major enabler of treatment adoption at scale. The public health system has been building this awareness through infrastructure and outreach, with 770 District NCD Clinics and 6,410 NCD clinics at Community Health Centres established under the national programme framework. These efforts are helping more people understand the benefits of efficient insulin delivery options, especially when doctors explain how pens and advanced devices can support better compliance and more consistent glycemic control.

For instance, the Health Ministry’s nationwide NCD screening campaign in 2025 was designed to achieve universal screening of individuals aged 30 years and above across Ayushman Arogya Mandir facilities and other healthcare institutions, demonstrating how awareness in India is now being backed by organized, large-scale case finding. As patients become more informed and more proactive, demand naturally shifts toward reliable, easy-to-use insulin delivery devices that make diabetes management feel more practical and less intimidating.

Download Free Sample Report

Key Market Challenges

Counterfeit Products

Counterfeit insulin delivery devices can compromise patient safety. Patients may unknowingly use substandard or ineffective devices, putting their health at risk. Substandard insulin delivery devices can lead to incorrect dosing, poor glycemic control, and adverse events. The presence of counterfeit products affects the market by undermining the revenue of legitimate manufacturers and distributors. This can lead to financial losses for the industry and reduced incentives for investment in research and development of new and improved devices. The presence of counterfeit insulin delivery devices can damage the reputation of established brands and manufacturers.

Patients and healthcare providers may lose trust in the authenticity and quality of these devices. Counterfeit products can create unfair competition in the market. Legitimate manufacturers face challenges in competing with counterfeit products that may be available at lower prices due to reduced quality control and safety standards. Counterfeit products can evade regulatory oversight and quality control measures. This undermines efforts by regulatory authorities to ensure the safety and efficacy of medical devices. The use of counterfeit insulin delivery devices can have severe public health implications, particularly when it results in adverse health outcomes or treatment failures for patients with diabetes.

Cultural Beliefs and Stigmas

In many Indian cultures, traditional remedies and alternative therapies hold deep-rooted significance. Some individuals may prefer traditional treatments over Western medicine, including insulin therapy. This can lead to delayed or inadequate diabetes management. A common cultural stigma is a fear of needles and injections. Many people with diabetes may avoid insulin therapy, especially if it involves syringes or needles. This can deter the adoption of insulin delivery devices. Cultural beliefs and misconceptions about diabetes and insulin can create barriers to proper treatment. Some individuals may associate diabetes with negative connotations or believe that insulin is harmful, leading to resistance in using insulin delivery devices.

Stigmatization of individuals with diabetes can lead to secrecy and reluctance to openly discuss the condition. This can prevent patients from seeking the best treatment options, including insulin delivery devices. Cultural dietary practices can affect diabetes management. Patients may struggle to adapt their traditional diets to their treatment plans, potentially affecting the effectiveness of insulin therapy. Cultural factors may contribute to a lack of awareness about diabetes and its management. Patients may not be well-informed about the available insulin delivery options. Family dynamics and cultural norms can influence healthcare decisions. In some cases, family members may be resistant to accepting insulin therapy for a loved one, leading to treatment delays.

Key Market Trends

Customization and Personalization

Manufacturers were offering a wider range of insulin delivery devices to accommodate individual preferences. This includes insulin pens, insulin pumps, patch pumps, and more. Patients could choose the device that aligns with their lifestyle and comfort. Insulin pumps with the ability to set variable basal rates gained popularity. Patients could personalize their insulin delivery based on their daily routines, physical activity, and other factors that affect insulin requirements. Customizable bolus dosing features allowed patients to adjust insulin doses before or after meals, depending on their specific dietary habits and glucose levels. Many insulin delivery devices were equipped with connectivity features, enabling patients to sync their devices with smartphone apps.

This allowed for real-time data tracking and personalization of insulin dosing. The ability to remotely monitor and adjust insulin delivery settings was a trend, particularly for patients who required caregiver support or healthcare professional oversight. Some insulin delivery devices incorporated smart algorithms that could predict and prevent hypoglycemia or hyperglycemia, offering a personalized approach to glycemic control. Manufacturers focused on creating user-friendly interfaces, making it easier for patients to customize and personalize their device settings.

Segmental Insights

Product Type Insights

Based on Product Type, the Pens emerged as the fastest growing segment in the Indian market for Insulin Delivery Devices during the forecast period. Insulin pens are increasingly preferred by patients due to their ease of use, portability, and convenience. Designed for self-administration, they allow diabetic patients to manage their insulin intake at home without requiring professional assistance. This user-friendly feature has made insulin pens particularly popular in urban and semi-urban areas. The growing prevalence of diabetes in India has significantly driven demand for insulin delivery devices, with more patients opting for insulin therapy. Insulin pens have become the preferred choice due to their precision and simplicity.

Technological advancements, including prefilled cartridges, adjustable dosage settings, and enhanced needle design, have improved both the effectiveness and comfort of insulin pens, making them even more appealing to patients and contributing to market growth. The pens' ability to provide better control over insulin dosage and their user-friendly design have also improved patient compliance, leading healthcare providers to increasingly prescribe them for more effective disease management. As self-management and home-based treatments become more common, insulin pens have emerged as a preferred solution for many patients. Their portability and ease of use outside healthcare settings have further driven their popularity and, consequently, the market's expansion.

Distribution Channel Insights

Based on Distribution Channels, Retail Pharmacies emerged as dominating segment in the India Insulin Delivery Devices Market in 2024.  Retail pharmacies are widely distributed across urban and rural areas in India, making insulin and insulin delivery devices easily accessible to a broad population. Patients can purchase these products without having to visit specialized healthcare facilities. Retail pharmacies often have an extensive distribution network, which allows them to reach even remote areas. This network enables the efficient delivery of insulin and insulin delivery devices to many patients.

Many insulin products, such as insulin pens and some insulin syringes, are available over the counter in India, which means patients can purchase them directly from retail pharmacies without a prescription. Retail pharmacies provide convenience to patients who may prefer to pick up their insulin and related devices while purchasing other healthcare or household products. Patients can also consult pharmacists for guidance on proper insulin administration. Pharmacists in retail pharmacies can offer basic education and information to patients about insulin therapy, insulin delivery devices, and proper storage, promoting better adherence to treatment plans. 

Download Free Sample Report

Regional Insights

Based on Region, North India emerged as dominating region in the India Insulin Delivery Devices Market in 2024. North India is one of the most densely populated regions in the country. With a higher population, there is a larger pool of potential diabetes patients, creating a significant demand for insulin and insulin delivery devices. North India includes major urban centers such as Delhi, NCR (National Capital Region), and several other rapidly urbanizing cities. Urbanization often leads to lifestyle changes, including dietary habits, which can contribute to a higher prevalence of diabetes.

Urban areas also tend to have better access to healthcare services, including diabetes management. The North Indian region is home to some of India's most advanced and well-equipped healthcare facilities, including hospitals, clinics, and specialized diabetes care centers. These institutions are more likely to offer a wide range of insulin delivery devices. North India has a higher concentration of healthcare professionals, including endocrinologists and diabetes educators. This can lead to better diabetes care, including the prescription and use of insulin delivery devices.

Recent Development

• In November 2025, Renu MedTech unveiled InsuPatch, a tubeless insulin patch pump designed specifically for advancing diabetes care in India. In November 2025, the launch stood out as a meaningful product innovation because it moved beyond conventional syringes, cartridges, and reusable pens toward a wearable pump format tailored to the needs of Indian diabetes patients.
• In May 2025, Novo Nordisk India publicly clarified that its top-selling insulin itself was not being withdrawn from the country, but that penfill and flexpen versions would affect a smaller subset of users while vial-based supply would continue. In May 2025, the company said roughly 10% of insulin users would be impacted by the device-format transition and that those patients would need to shift either to newer-generation insulin options or to vial-based administration depending on physician advice.

Key Market Players

• Biocon Limited
• India Medtronic Pvt. Ltd.
• Roche Products (India) Pvt. Ltd.
• Becton Dickinson India Private Limited
• Novo Nordisk India Pvt Ltd
• Sanofi Healthcare India Pvt. Ltd.
• Eli Lilly & Co (India) Pvt. Ltd
• Abbott India Ltd
• B. Braun Medical SE

Report Scope:

In this report, the India Insulin Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Insulin Delivery Devices Market, By Product Type:

o   Pens

o   Pumps

o   Pen Needles

o   Others

• India Insulin Delivery Devices Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

o   Others

• India Insulin Delivery Devices Market, By End User:

o   Hospitals & Clinics

o   Homecare

o   Others

• India Insulin Delivery Devices Market, By Region:

o   North India

o   South India

o   East India

o   West India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Insulin Delivery Devices Market.

Available Customizations:

India Insulin Delivery Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Insulin Delivery Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]